Test Price
1,200 AED✅ Home Collection Available
BCR‑ABL1 Quantitative (CML MRD1) Monitoring Test in Dubai | 1,200 AED
Executive Summary & Core Metrics
UAE-Compliant Molecular Monitoring for Chronic Myeloid Leukemia
- 99.9% Diagnostic Sensitivity – ISO 9001:2015‑accredited laboratory (Cert: INT/EGQ/2509DA/3139) using real‑time quantitative PCR with International Scale (IS) calibration.
- Premium Logistics – VIP mobile phlebotomy & temperature‑controlled cold‑chain home collection available daily from 8 AM to 11 PM. Samples transported at 2‑8 °C within 60 minutes.
- Clinical Guidance – Post‑test telephonic consultation explaining BCR‑ABL1 transcript levels, molecular remission status, and recommended follow‑up, fully aligned with DHA standards.
- Insurance & Billing – Direct verification of coverage over WhatsApp: +971 54 548 8731. We handle pre‑approvals for leading UAE networks.
Test Overview & Methodology
This highly sensitive blood test measures the BCR‑ABL1 fusion transcript, the molecular hallmark of chronic myeloid leukemia (CML). By detecting even one leukemia cell among 100,000 normal cells, it guides targeted therapy decisions (e.g., TKI dose adjustments) and confirms deep molecular response. The methodology employs real‑time quantitative PCR standardized to the International Scale (IS), ensuring results are comparable across laboratories worldwide.
| Feature | Our BCR‑ABL1 MRD Test | Closest Alternative (Standard RT‑PCR) |
|---|---|---|
| Methodology | Real‑time quantitative PCR (qPCR) standardized to the International Scale (IS) | Conventional RT‑PCR; may not be IS‑calibrated |
| Sensitivity (MRD depth) | Up to MR4.5 (0.001% IS) – detects 1 CML cell in 100,000 | Typically MR3.0 (0.1% IS) or higher |
| Turnaround Time | 24 hours by phone; 36 hours via email (3rd working day report) | 5–7 working days |
| Sample Requirement | 2–3 mL peripheral whole blood (EDTA tube) – no bone marrow needed | Often requires bone marrow aspirate |
| UAE Regulatory Status | DHA‑listed molecular test, fully compliant with Federal Law No. 2 of 2019 and PDPL | Variable; may lack ISO 9001:2015 certification |
Physician Insight & Safety Protocols
“Molecular monitoring with BCR‑ABL1 qPCR is the cornerstone of modern CML care. A single result must always be interpreted alongside complete blood counts, kinase domain mutation analysis, and adherence history. At DNA Labs UAE, our integrated tele‑counseling ensures that every patient understands what a 0.01% IS really means before making any treatment changes.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Medication Advisory
⚠ Medication Warning
Do not discontinue or adjust prescribed tyrosine kinase inhibitors (imatinib, dasatinib, nilotinib, etc.) based on this test alone. Always consult your treating oncologist. Abrupt cessation can lead to rapid disease relapse.
Exclusion Criteria & Emergency Red Flags
- Recent blood transfusion (less than 4 weeks) may transiently lower BCR‑ABL1 levels – reschedule if possible.
- Active uncontrolled infection or major surgery in the last 2 weeks – inform the phlebotomist.
- ER Red Flags: Seek immediate emergency care if you experience sudden high fever above 38.5°C, uncontrollable bleeding, severe bone pain, or signs of neurological deficit (blast crisis).
- Pregnancy or breastfeeding – test may still be performed but interpretation requires caution; discuss with your physician.
Patient FAQ & Clinical Guidance
1. What exactly does the BCR‑ABL1 quantitative test measure?
It quantifies the BCR‑ABL1 fusion gene transcript in your blood to monitor minimal residual leukemia after CML treatment. Results are reported as a percentage on the International Scale, indicating the molecular burden of disease.
2. How often should I repeat this if I have CML?
Guidelines recommend every 3 months until a major molecular response is achieved, then every 3 to 6 months to ensure sustained deep remission. Your specialist will tailor the frequency based on your clinical profile.
3. What does an undetectable result (MR4.5) mean?
It signifies a deep molecular response with less than 0.001% leukemia cells remaining. This may allow discussion of treatment‑free remission with your oncologist, but requires rigorous ongoing monitoring and shared decision‑making.
UAE Regulatory & Data Privacy Adherence
Data Privacy & Clinical Governance
- All personal data processed in accordance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL).
- Health information handled under Federal Law No. 2 of 2019 concerning the use of information and communication technology in health fields.
- Clinical safety and patient consent governed by Federal Decree-Law No. 4 of 2016 on Medical Liability.
- DNA Labs UAE is a DHA-licensed facility (License No. 1143) and complies with all applicable regulatory standards.
Clinical & Logistical Metadata
| Test Name | BCR‑ABL1 Quantitative (CML MRD1) Monitoring |
| Price (AED) | 1,200 |
| Turnaround Time | 24 hours (verbal) / 36 hours (written report) |
| Sample Type / Matrix | Peripheral whole blood (EDTA tube) – VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection Available Daily from 8 AM to 11 PM. |
| Methodology Used | Real‑time quantitative PCR (qPCR) calibrated to the International Scale (IS) |
| ICD-10-CM Code | C92.10 (Chronic myeloid leukemia, BCR/ABL-positive, not in remission) |
| LOINC Code | 5196-1 (BCR/ABL1 transcript [Ratio] in Blood by PCR) |
| DHA Facility License & Laboratory Address | DHA License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians